A phase I/II basket trial for Glioblastoma, Neuroendocrine tumors, Head and neck cancer, Non-small cell lung cancer and pancreatic cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium-68 NOTA AE105 (Primary)
Indications Glioblastoma; Head and neck cancer; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer
Focus Adverse reactions

16 Feb 2024 New trial record
13 Feb 2024 According to Curasight media release, First patients expected to be dosed in the beginning of 2025 with expected first efficacy data in 2025.
13 Feb 2024 According to Curasight media release, company resolved on a new issue of shares with preferential rights for the Companys existing shareholders of up to DKK 51.2 million before transaction costs which will be used for planning and enrolment of the first patients in a therapy phase I/IIa basket trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com